Article · Testing

Fewer test scripts do not automatically mean better assurance

How to judge a testing change by risk coverage and evidence quality instead of script counts.

CSVtoCSA editorial · 2 min read · Published · Summary updated 2026-09-21 · Version 1.1

A team reduces its test-script count from 120 to 45 and describes the result as a successful CSA transformation. That number tells us something about the work product, but very little about confidence in the system.

What did the removed tests cover? What evidence replaced them? Were important failures examined more thoroughly? Did the team discover problems that its previous approach would have missed? Those questions determine whether the change improved assurance.

Consider a CAPA workflow

Fictional example. The old package contains separate scripts for opening each screen, entering ordinary text, and navigating between tabs. It contains only one successful approval path. An API can also update CAPA state, but the package never challenges it.

The revised approach combines standard navigation checks, reviews suitable supplier evidence, and uses an exploratory charter for reassignment and cancellation. It adds controlled tests for required approvals, invalid severity values, unauthorized API updates, and existing records after an update.

The value comes from addressing previously weak evidence. The lower script count is a possible consequence of that redesign, not the goal that proves its success.

What to measure instead

Look at coverage of important failure modes, quality of expected results, unresolved evidence gaps, defect findings and their implications, reviewability of records, and operational outcomes. Effort and cycle time can be reported too, but describe how they were measured and what changed.

If a claimed 30% time reduction excludes time spent correcting false findings or creating new monitoring work, the claim is incomplete. Define the process boundary before presenting an efficiency result.

When more detail is appropriate

A boundary calculation, a complex migration reconciliation, or a critical interface recovery scenario may need more explicit conditions and evidence than before. Risk-informed assurance can increase work in an area where confidence was weak.

A useful review question

Ask the team to explain one removed activity and one strengthened activity. For each, request the failure, existing evidence, gap, and decision. If the rationale is only “CSA requires less documentation,” revisit the approach.

The practical aim is a supportable decision about use. A test inventory is useful when it helps establish that decision, not when its size becomes a performance target.

Practitioner interpretation; apply the sources within their scope and follow your approved procedures. Prepared with AI assistance and editorial responsibility. Original publication and source links are retained; this revision updates the summary and resource navigation.

Relevant regulations and guidance

These sources apply within their stated scope. The suggested worksheet fields, test designs and fictional decisions are practitioner recommendations, unless a source requirement is expressly identified. Completing a template does not establish compliance.

Computer Software Assurance for Production and Quality Management System Software ↗

Regulatory guidance / GMP guideline · United States · February 2026

Scope: Medical-device manufacturers assuring software used in production or their quality management system.

Relevance: For medical-device production or QMS software, supports selecting assurance activities from intended use, risk and available evidence. It is nonbinding guidance and does not determine other sectors’ obligations.

Status: Final / published · Checked 2026-09-21

Publication identity, scope and status checked against the linked official source. This is not an independent audit of every retained guide statement.

Read source details and applicability →

EudraLex Volume 4, Annex 11 — Computerised Systems ↗

Regulatory guidance / GMP guideline · European Union · January 2011 revision

Scope: Computerised systems supporting activities in the applicable EU pharmaceutical GMP context.

Relevance: For computerised systems used in EU GMP activities, informs lifecycle, supplier and record controls. Confirm applicability to the actual activity; the example does not establish it.

Status: Final / published · Checked 2026-09-21

The Commission index confirms the January 2011 operative revision. The linked PDF could not be retrieved in this check; retained detailed section mappings need review against an authorized copy.

Read source details and applicability →
Was this useful? Leave feedback

Was this resource useful?

Tell us what helped and what could be clearer. Usefulness feedback does not establish technical validity or regulatory compliance.

Loading contribution options…

Questions and moderated discussion

Questions and discussion

Ask a question or share a perspective. Contributions are reviewed before publication.

Loading contribution options…

Suggest a correction

Sent privately to the editorial moderation queue. Your account email and correction are not published as a comment. Do not include confidential or personal information.

Resource: Fewer test scripts do not automatically mean better assurance

Loading sign-in status…

Correction details